Chandrasekar Gopalakrishnan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8341575/publications.pdf

Version: 2024-02-01

26 papers 725 citations

758635 12 h-index 552369 26 g-index

27 all docs

27 docs citations

times ranked

27

1067 citing authors

#	Article	IF	CITATIONS
1	Development of a Medicare Claims–Based Model to Predict Persistent Highâ€Dose Opioid Use After Total Knee Replacement. Arthritis Care and Research, 2022, 74, 1342-1348.	1.5	1
2	Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 1051.	3.8	14
3	Comparison of measures of medication adherence from pharmacy dispensing and insurer claims data. Health Services Research, 2021, , .	1.0	5
4	Time to end the misuse of race in medicine: cases from nephrology. BMJ, The, 2021, 375, n2435.	3.0	6
5	Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. Clinical Pharmacology and Therapeutics, 2020, 107, 1334-1342.	2.3	2
6	Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation. Clinical Pharmacology and Therapeutics, 2020, 107, 1405-1419.	2.3	12
7	Prevalence and Impact of Having Multiple Barriers to Medication Adherence in Nonadherent Patients With Poorly Controlled Cardiometabolic Disease. American Journal of Cardiology, 2020, 125, 376-382.	0.7	16
8	Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. JAMA Internal Medicine, 2020, 180, 1596.	2.6	48
9	Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. American Heart Journal, 2020, 228, 36-43.	1.2	11
10	Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride. Diabetes Care, 2019, 42, 2204-2210.	4.3	81
11	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clinical Pharmacology and Therapeutics, 2019, 105, 1513-1521.	2.3	10
12	Evaluating utilization patterns of oral anticoagulants in routine care. Journal of Thrombosis and Haemostasis, 2019, 17, 1033-1043.	1.9	10
13	Cardiovascular safety of linagliptin compared with other oral glucoseâ€lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care. Diabetes, Obesity and Metabolism, 2019, 21, 1824-1836.	2.2	4
14	Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005173.	0.9	8
15	Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records. Clinical Pharmacology and Therapeutics, 2019, 105, 979-993.	2.3	11
16	Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors. Endocrinology, Diabetes and Metabolism, 2018, 1, e00005.	1.0	7
17	The relative benefits of claims and electronic health record data for predicting medication adherence trajectory. American Heart Journal, 2018, 197, 153-162.	1.2	26
18	Claimsâ€based studies of oral glucoseâ€lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes, Obesity and Metabolism, 2018, 20, 974-984.	2.2	63

#	Article	IF	CITATIONS
19	Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes. JAMA Internal Medicine, 2018, 178, 1182.	2.6	71
20	Metformin use and risk of lactic acidosis in people with diabetes with and without renal impairment: a cohort study in Denmark and the <scp>UK</scp> . Diabetic Medicine, 2017, 34, 485-489.	1.2	19
21	Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. Arthritis and Rheumatology, 2016, 68, 1183-1189.	2.9	27
22	Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial. American Heart Journal, 2016, 180, 90-97.	1.2	24
23	Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. Arthritis Care and Research, 2016, 68, 1078-1088.	1.5	24
24	Comparative cardiovascular safety of glucagonâ€like peptideâ€l receptor agonists versus other antidiabetic drugs in routine care: a cohort study. Diabetes, Obesity and Metabolism, 2016, 18, 755-765.	2.2	26
25	Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn. JAMA - Journal of the American Medical Association, 2015, 313, 2142.	3.8	198
26	Abstract 17137: Safety and Effectiveness of Dabigatran Relative to Warfarin in Routine Clinical Practice - New Interim Results of Long-term Study Program. Circulation, 2015, 132, .	1.6	1